What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?
In the case of Genentech Inc., nothing.
The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.
Study outcome won't sway company on eye drug
A team of researchers from Northwestern University have developed a 3D-printable ink that produces synthetic bone...
The internet was outraged earlier this month after a new report revealed the sugar industry paid...
A drug designed for patients with Duchenne muscular dystrophy was shown in a study with mice...
Gonorrhea appears to be developing resistance to the two antibiotics that constitute the last available treatment...
